...
首页> 外文期刊>Molecular cancer therapeutics >Beta-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells.
【24h】

Beta-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells.

机译:β-紫罗兰酮可抑制大鼠结肠异常隐窝灶的形成,抑制细胞生长,并诱导人结肠癌细胞中的类维生素A X受体-α。

获取原文
获取原文并翻译 | 示例
           

摘要

Beta-ionone, an end-ring analogue of beta-carotenoid, which is a constituent of vegetables and fruits, has been analyzed for colon cancer chemoprevention and treatment. beta-Ionone induced cell growth inhibition and apoptosis in human colon cancer HCT116 cell line. We tested the in vivo chemopreventive efficacy in rat colon carcinogenesis model using aberrant crypt foci (ACF) as endpoint marker. HCT116 cells treated with subtoxic concentrations of beta-ionone resulted dose-dependent cell growth suppression with G1-S-phase growth arrest and significant induction of apoptosis. beta-Ionone up-regulated expression of retinoid X receptor-alpha mRNA dose-dependently in HCT116 cells. To evaluate inhibitory properties of beta-ionone on colonic ACF, 7-week-old male F344 rats were fed experimental diets containing 0%, 0.1%, or 0.2% beta-ionone. After 1 week, rats received s.c. injections of azoxymethane, 15 mg/kg body weight, once weekly for 2 weeks. Rats were continued on respective experimental diets and sacrificed 8 weeks after the azoxymethane treatment. Colons were evaluated histopathologically for ACF. Administration of dietary 0.1% and 0.2% beta-ionone significantly suppressed total colonic ACF formation up to 34% to 38% (P<0.0002 to P<0.0009), respectively, when compared with control group. Importantly, rats fed beta-ionone showed >55% inhibition (P<0.0001) of foci containing four or more aberrant crypts. Results from in vitro and in vivo bioassay clearly suggest that beta-ionone could be further developed for prevention and treatment of colon cancer.
机译:β-紫罗兰酮是一种β-类胡萝卜素的末端环类似物,它是蔬菜和水果的成分,已被分析用于结肠癌的化学预防和治疗。 β-紫罗兰酮诱导人结肠癌HCT116细胞系的细胞生长抑制和凋亡。我们使用异常隐窝灶(ACF)作为终点标记,在大鼠结肠癌发生模型中测试了体内化学预防功效。用亚毒性浓度的β-紫罗兰酮处理的HCT116细胞可抑制G1-S期生长并显着诱导凋亡,从而抑制了剂量依赖性细胞的生长。 β-紫罗兰酮上调HCT116细胞中类视色素X受体-αmRNA的表达。为了评估β-紫罗兰酮对结肠ACF的抑制特性,给7周大的雄性F344大鼠喂食含有0%,0.1%或0.2%β-紫罗兰酮的实验饮食。 1周后,大鼠接受皮下注射。每周一次注射15 mg / kg体重的乙氧基甲烷,持续2周。大鼠继续接受各自的实验饮食,并在甲氧甲烷处理后8周处死。对结肠进行ACF的病理组织学评价。与对照组相比,饮食中添加0.1%和0.2%的β-紫罗兰酮可显着抑制总结肠ACF的形成,分别高达34%至38%(P <0.0002至P <0.0009)。重要的是,喂食β-紫罗兰酮的大鼠对包含四个或更多异常隐窝的病灶显示出> 55%的抑制作用(P <0.0001)。体外和体内生物测定的结果清楚地表明,β-紫罗兰酮可以进一步开发用于预防和治疗结肠癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号